These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Nanobodies: New avenues for imaging, stabilizing and modulating GPCRs. De Groof TWM; Bobkov V; Heukers R; Smit MJ Mol Cell Endocrinol; 2019 Mar; 484():15-24. PubMed ID: 30690070 [TBL] [Abstract][Full Text] [Related]
8. Yeast surface display platform for rapid discovery of conformationally selective nanobodies. McMahon C; Baier AS; Pascolutti R; Wegrecki M; Zheng S; Ong JX; Erlandson SC; Hilger D; Rasmussen SGF; Ring AM; Manglik A; Kruse AC Nat Struct Mol Biol; 2018 Mar; 25(3):289-296. PubMed ID: 29434346 [TBL] [Abstract][Full Text] [Related]
9. Generation and characterization of nanobodies targeting GPCR. Zhang S; Fan Z; Liu J Biophys Rep; 2024 Feb; 10(1):22-30. PubMed ID: 38737476 [TBL] [Abstract][Full Text] [Related]
10. Nanobodies to Study G Protein-Coupled Receptor Structure and Function. Manglik A; Kobilka BK; Steyaert J Annu Rev Pharmacol Toxicol; 2017 Jan; 57():19-37. PubMed ID: 27959623 [TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension. Israili ZH J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085 [TBL] [Abstract][Full Text] [Related]
12. Angiotensin II inhibits DDAH1-nNOS signaling via AT1R and μOR dimerization to modulate blood pressure control in the central nervous system. Sun GC; Wong TY; Chen HH; Ho CY; Yeh TC; Ho WY; Tseng CJ; Cheng PW Clin Sci (Lond); 2019 Dec; 133(23):2401-2413. PubMed ID: 31755934 [TBL] [Abstract][Full Text] [Related]
13. Angiotensin II receptor blockade: an innovative approach to cardiovascular pharmacotherapy. Eberhardt RT; Kevak RM; Kang PM; Frishman WH J Clin Pharmacol; 1993 Nov; 33(11):1023-38. PubMed ID: 8300885 [TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of Nanobodies targeting the EphA4 receptor. Schoonaert L; Rué L; Roucourt B; Timmers M; Little S; Chávez-Gutiérrez L; Dewilde M; Joyce P; Curnock A; Weber P; Haustraete J; Hassanzadeh-Ghassabeh G; De Strooper B; Van Den Bosch L; Van Damme P; Lemmens R; Robberecht W J Biol Chem; 2017 Jul; 292(27):11452-11465. PubMed ID: 28526745 [TBL] [Abstract][Full Text] [Related]
15. Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies. Romao E; Morales-Yanez F; Hu Y; Crauwels M; De Pauw P; Hassanzadeh GG; Devoogdt N; Ackaert C; Vincke C; Muyldermans S Curr Pharm Des; 2016; 22(43):6500-6518. PubMed ID: 27669966 [TBL] [Abstract][Full Text] [Related]
17. Angiotensin II type 2 receptors contribute to vascular responses in spontaneously hypertensive rats treated with angiotensin II type 1 receptor antagonists. Cosentino F; Savoia C; De Paolis P; Francia P; Russo A; Maffei A; Venturelli V; Schiavoni M; Lembo G; Volpe M Am J Hypertens; 2005 Apr; 18(4 Pt 1):493-9. PubMed ID: 15831358 [TBL] [Abstract][Full Text] [Related]
18. Evidence that prostaglandins mediate the antihypertensive actions of angiotensin-(1-7) during chronic blockade of the renin-angiotensin system. Iyer SN; Yamada K; Diz DI; Ferrario CM; Chappell MC J Cardiovasc Pharmacol; 2000 Jul; 36(1):109-17. PubMed ID: 10892668 [TBL] [Abstract][Full Text] [Related]
19. The Impact of Nanobodies on G Protein-Coupled Receptor Structural Biology and Their Potential as Therapeutic Agents. Salom D; Wu A; Liu CC; Palczewski K Mol Pharmacol; 2024 Sep; 106(4):155-163. PubMed ID: 39107078 [TBL] [Abstract][Full Text] [Related]
20. The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma. Coulson R; Liew SH; Connelly AA; Yee NS; Deb S; Kumar B; Vargas AC; O'Toole SA; Parslow AC; Poh A; Putoczki T; Morrow RJ; Alorro M; Lazarus KA; Yeap EFW; Walton KL; Harrison CA; Hannan NJ; George AJ; Clyne CD; Ernst M; Allen AM; Chand AL Oncotarget; 2017 Mar; 8(12):18640-18656. PubMed ID: 28416734 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]